GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Price-to-Owner-Earnings

Dechra Pharmaceuticals (LSE:DPH) Price-to-Owner-Earnings : (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-05-21), Dechra Pharmaceuticals's share price is £38.66. Dechra Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Dechra Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Dechra Pharmaceuticals was 220.00. The lowest was 11.62. And the median was 62.19.


LSE:DPH's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.27
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-21), Dechra Pharmaceuticals's share price is £38.66. Dechra Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.25. Therefore, Dechra Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-05-21), Dechra Pharmaceuticals's share price is £38.66. Dechra Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was £0.95. Therefore, Dechra Pharmaceuticals's PE Ratio without NRI for today is 40.91.

During the past 13 years, Dechra Pharmaceuticals's highest PE Ratio without NRI was 49.63. The lowest was 18.91. And the median was 30.98.


Dechra Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Dechra Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Price-to-Owner-Earnings Chart

Dechra Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 198.99 122.15 67.13 54.72 -

Dechra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.13 - 54.72 - -

Competitive Comparison of Dechra Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dechra Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's Price-to-Owner-Earnings falls into.



Dechra Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Dechra Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=38.66/-0.44
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dechra Pharmaceuticals  (LSE:DPH) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Dechra Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Dechra Pharmaceuticals (LSE:DPH) Business Description

Traded in Other Exchanges
Address
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines